Walleye Capital LLC Buys 414,884 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Walleye Capital LLC boosted its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 2,119.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 434,460 shares of the company's stock after buying an additional 414,884 shares during the quarter. Walleye Capital LLC owned approximately 0.32% of Vir Biotechnology worth $3,189,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Vir Biotechnology during the fourth quarter worth about $177,000. Quinn Opportunity Partners LLC bought a new position in Vir Biotechnology during the 4th quarter worth approximately $484,000. Renaissance Technologies LLC lifted its position in shares of Vir Biotechnology by 4.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company's stock worth $9,084,000 after purchasing an additional 55,300 shares during the period. Invesco Ltd. boosted its stake in shares of Vir Biotechnology by 0.6% in the 4th quarter. Invesco Ltd. now owns 398,772 shares of the company's stock valued at $2,927,000 after purchasing an additional 2,574 shares during the last quarter. Finally, Polymer Capital Management US LLC acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth $101,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on VIR shares. Barclays upped their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. The Goldman Sachs Group lowered their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a report on Thursday, April 17th. JPMorgan Chase & Co. raised their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. HC Wainwright reissued a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Finally, Leerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Vir Biotechnology has a consensus rating of "Moderate Buy" and an average target price of $33.57.

Insiders Place Their Bets

In related news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the sale, the chief executive officer now directly owns 769,505 shares in the company, valued at approximately $4,578,554.75. The trade was a 9.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at $726,264.40. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,611 shares of company stock valued at $663,525 in the last three months. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR traded up $0.18 during midday trading on Wednesday, hitting $5.98. 426,266 shares of the company's stock were exchanged, compared to its average volume of 1,334,799. Vir Biotechnology, Inc. has a 12 month low of $4.95 and a 12 month high of $14.45. The company has a market cap of $820.12 million, a PE ratio of -1.53 and a beta of 1.14. The stock has a 50 day moving average price of $7.11 and a 200-day moving average price of $8.08.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. On average, analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).